From Data to Decisions: Leveraging Artificial Intelligence and Machine Learning in Combating Antimicrobial Resistance – a Comprehensive Review

The emergence of drug-resistant bacteria poses a significant challenge to modern medicine. In response, Artificial Intelligence (AI) and Machine Learning (ML) algorithms have emerged as powerful tools for combating antimicrobial resistance (AMR). This review aims to explore the role of AI/ML in AMR management, with a focus on identifying pathogens, understanding resistance patterns, predicting treatment outcomes, and discovering new antibiotic agents. Recent advancements in AI/ML have enabled the efficient analysis of large datasets, facilitating the reliable prediction of AMR trends and treatment responses with minimal human intervention. ML algorithms can analyze genomic data to identify genetic markers associated with antibiotic resistance, enabling the development of targeted treatment strategies. Additionally, AI/ML techniques show promise in optimizing drug administration and developing alternatives to traditional antibiotics. By analyzing patient data and clinical outcomes, these technologies can assist healthcare providers in diagnosing infections, evaluating their severity, and selecting appropriate antimicrobial therapies. While integration of AI/ML in clinical settings is still in its infancy, advancements in data quality and algorithm development suggest that widespread clinical adoption is forthcoming. In conclusion, AI/ML holds significant promise for improving AMR management and treatment outcome.

Saved in:
Bibliographic Details
Main Authors: Pérez de Lastra, José Manuel, Wardell, Samuel J. T., Pal, Tarun, de la Fuente-Núñez, César, Pletzer, Daniel
Other Authors: Ministerio de Ciencia e Innovación (España)
Format: artículo biblioteca
Language:English
Published: Springer Nature 2024-08-01
Subjects:AI/ML, pathogen identification, antibiotic resistance, antibiotic stewardship, personalized treatment, antimicrobial peptides, artificial intelligence, machine learning, antimicrobial resistance,
Online Access:http://hdl.handle.net/10261/364991
Tags: Add Tag
No Tags, Be the first to tag this record!
id dig-ipna-es-10261-364991
record_format koha
institution IPNA ES
collection DSpace
country España
countrycode ES
component Bibliográfico
access En linea
databasecode dig-ipna-es
tag biblioteca
region Europa del Sur
libraryname Biblioteca del IPNA España
language English
topic AI/ML
pathogen identification
antibiotic resistance
antibiotic stewardship
personalized treatment
antimicrobial peptides
artificial intelligence
machine learning
antimicrobial resistance
AI/ML
pathogen identification
antibiotic resistance
antibiotic stewardship
personalized treatment
antimicrobial peptides
artificial intelligence
machine learning
antimicrobial resistance
spellingShingle AI/ML
pathogen identification
antibiotic resistance
antibiotic stewardship
personalized treatment
antimicrobial peptides
artificial intelligence
machine learning
antimicrobial resistance
AI/ML
pathogen identification
antibiotic resistance
antibiotic stewardship
personalized treatment
antimicrobial peptides
artificial intelligence
machine learning
antimicrobial resistance
Pérez de Lastra, José Manuel
Wardell, Samuel J. T.
Pal, Tarun
de la Fuente-Núñez, César
Pletzer, Daniel
From Data to Decisions: Leveraging Artificial Intelligence and Machine Learning in Combating Antimicrobial Resistance – a Comprehensive Review
description The emergence of drug-resistant bacteria poses a significant challenge to modern medicine. In response, Artificial Intelligence (AI) and Machine Learning (ML) algorithms have emerged as powerful tools for combating antimicrobial resistance (AMR). This review aims to explore the role of AI/ML in AMR management, with a focus on identifying pathogens, understanding resistance patterns, predicting treatment outcomes, and discovering new antibiotic agents. Recent advancements in AI/ML have enabled the efficient analysis of large datasets, facilitating the reliable prediction of AMR trends and treatment responses with minimal human intervention. ML algorithms can analyze genomic data to identify genetic markers associated with antibiotic resistance, enabling the development of targeted treatment strategies. Additionally, AI/ML techniques show promise in optimizing drug administration and developing alternatives to traditional antibiotics. By analyzing patient data and clinical outcomes, these technologies can assist healthcare providers in diagnosing infections, evaluating their severity, and selecting appropriate antimicrobial therapies. While integration of AI/ML in clinical settings is still in its infancy, advancements in data quality and algorithm development suggest that widespread clinical adoption is forthcoming. In conclusion, AI/ML holds significant promise for improving AMR management and treatment outcome.
author2 Ministerio de Ciencia e Innovación (España)
author_facet Ministerio de Ciencia e Innovación (España)
Pérez de Lastra, José Manuel
Wardell, Samuel J. T.
Pal, Tarun
de la Fuente-Núñez, César
Pletzer, Daniel
format artículo
topic_facet AI/ML
pathogen identification
antibiotic resistance
antibiotic stewardship
personalized treatment
antimicrobial peptides
artificial intelligence
machine learning
antimicrobial resistance
author Pérez de Lastra, José Manuel
Wardell, Samuel J. T.
Pal, Tarun
de la Fuente-Núñez, César
Pletzer, Daniel
author_sort Pérez de Lastra, José Manuel
title From Data to Decisions: Leveraging Artificial Intelligence and Machine Learning in Combating Antimicrobial Resistance – a Comprehensive Review
title_short From Data to Decisions: Leveraging Artificial Intelligence and Machine Learning in Combating Antimicrobial Resistance – a Comprehensive Review
title_full From Data to Decisions: Leveraging Artificial Intelligence and Machine Learning in Combating Antimicrobial Resistance – a Comprehensive Review
title_fullStr From Data to Decisions: Leveraging Artificial Intelligence and Machine Learning in Combating Antimicrobial Resistance – a Comprehensive Review
title_full_unstemmed From Data to Decisions: Leveraging Artificial Intelligence and Machine Learning in Combating Antimicrobial Resistance – a Comprehensive Review
title_sort from data to decisions: leveraging artificial intelligence and machine learning in combating antimicrobial resistance – a comprehensive review
publisher Springer Nature
publishDate 2024-08-01
url http://hdl.handle.net/10261/364991
work_keys_str_mv AT perezdelastrajosemanuel fromdatatodecisionsleveragingartificialintelligenceandmachinelearningincombatingantimicrobialresistanceacomprehensivereview
AT wardellsamueljt fromdatatodecisionsleveragingartificialintelligenceandmachinelearningincombatingantimicrobialresistanceacomprehensivereview
AT paltarun fromdatatodecisionsleveragingartificialintelligenceandmachinelearningincombatingantimicrobialresistanceacomprehensivereview
AT delafuentenunezcesar fromdatatodecisionsleveragingartificialintelligenceandmachinelearningincombatingantimicrobialresistanceacomprehensivereview
AT pletzerdaniel fromdatatodecisionsleveragingartificialintelligenceandmachinelearningincombatingantimicrobialresistanceacomprehensivereview
_version_ 1809105118570741760
spelling dig-ipna-es-10261-3649912024-08-01T11:42:04Z From Data to Decisions: Leveraging Artificial Intelligence and Machine Learning in Combating Antimicrobial Resistance – a Comprehensive Review Pérez de Lastra, José Manuel Wardell, Samuel J. T. Pal, Tarun de la Fuente-Núñez, César Pletzer, Daniel Ministerio de Ciencia e Innovación (España) Consejo Superior de Investigaciones Científicas (CSIC) University of Pennsylvania AIChE Foundation International Association for Dental Research Procter & Gamble United Therapeutics Corporation BBRF Penn Health-Tech National Institutes of Health (US) Defense Threat Reduction Agency (US) Pérez de Lastra, José Manuel [0000-0003-4663-5565] Wardell, Samuel J. T. [0000-0001-6886-6933] Pal, Tarun [0000-0002-4344-0351] de la Fuente-Núñez, César [0000-0002-2005-5629] Pletzer, Daniel [0000-0001-5750-7505] AI/ML pathogen identification antibiotic resistance antibiotic stewardship personalized treatment antimicrobial peptides artificial intelligence machine learning antimicrobial resistance The emergence of drug-resistant bacteria poses a significant challenge to modern medicine. In response, Artificial Intelligence (AI) and Machine Learning (ML) algorithms have emerged as powerful tools for combating antimicrobial resistance (AMR). This review aims to explore the role of AI/ML in AMR management, with a focus on identifying pathogens, understanding resistance patterns, predicting treatment outcomes, and discovering new antibiotic agents. Recent advancements in AI/ML have enabled the efficient analysis of large datasets, facilitating the reliable prediction of AMR trends and treatment responses with minimal human intervention. ML algorithms can analyze genomic data to identify genetic markers associated with antibiotic resistance, enabling the development of targeted treatment strategies. Additionally, AI/ML techniques show promise in optimizing drug administration and developing alternatives to traditional antibiotics. By analyzing patient data and clinical outcomes, these technologies can assist healthcare providers in diagnosing infections, evaluating their severity, and selecting appropriate antimicrobial therapies. While integration of AI/ML in clinical settings is still in its infancy, advancements in data quality and algorithm development suggest that widespread clinical adoption is forthcoming. In conclusion, AI/ML holds significant promise for improving AMR management and treatment outcome. Open Access funding enabled and organized by CAUL and its Member Institutions JMPL was supported by the State Plan for Scientific, Technical Research and Innovation 2021–2023 from the Spanish Ministry of Science and Innovation (project PLEC2022-009507) and by the COCREA innovation project of the Spanish National Research Council (CSIC) to promote solutions to global challenges. Cesar de la Fuente-Nunez holds a Presidential Professorship at the University of Pennsylvania, is a recipient of the Langer Prize by the AIChE Foundation, and acknowledges funding from the IADR Innovation in Oral Care Award, the Procter & Gamble Company, United Therapeutics, a BBRF Young Investigator Grant, the Nemirovsky Prize, Penn Health-Tech Accelerator Award, the Dean’s Innovation Fund from the Perelman School of Medicine at the University of Pennsylvania, the National Institute of General Medical Sciences of the National Institutes of Health under award number R35GM138201, and the Defense Threat Reduction Agency (DTRA; HDTRA1-22-10031, HDTRA1-21-1-0014, and HDTRA1-23-1-0001). Peer reviewed 2024-08-01T11:42:03Z 2024-08-01T11:42:03Z 2024-08-01 artículo Journal of Medical Systems, 48(71): 1-14 (2024) 0148-5598 http://hdl.handle.net/10261/364991 10.1007/s10916-024-02089-5 1573-689X en #PLACEHOLDER_PARENT_METADATA_VALUE# info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023/PLEC2022-009507/ES/Caseinolytic Protease P (ClpP) Agonists: Small Molecules with a New Mechanism of Action for the Treatment of Multidrugs Resistant Bacterial Infections/ Publisher's version https://doi.org/10.1007/s10916-024-02089-5 Sí open Springer Nature